The BioFire® Respiratory 2.1-EZ
(RP2.1- EZ) Panel*

With SARS-CoV-2

Now authorized by the FDA through an Emergency Use Authorization, the BioFire RP2.1-EZ Panel uses a syndromic approach to accurately detect and identify a wide range of pathogens—including SARS-CoV-2. The panel identifies a menu of 19 respiratory targets in one multiplex PCR test, with results in about 45 minutes. As a healthcare provider, this means your patients can receive the right treatment the first time, potentially leading to higher patient satisfaction and lower costs. The BioFire RP2.1-EZ Panel is designed to run on the CLIA-waived BioFire® FilmArray® 2.0 EZ Configuration System.